Aprotinin
in liver transplantation 595
renal risk in cardiac surgery and ..... 2207(L)
vs. tranexamic acid in cardiac surgery ..... 319(E), 327, 2208(L), 2209(R)
Aralast 1959
Arsine toxicity 1267, 1576
Arterial blood gases 186
Asian population 2128
ATP
PLT storage and 973
RBC storage and 50, 137
Autoimmune hemolytic anemia 90, 741, 1859
Autologous blood donation
baboon 8S:1S
cord RBCs 1049
in-line filtration 811
preoperative 934, 1484
repeated, blood pressure in 934
rHu-EPO therapy 1616

B

B cell recovery,from leukodepletion filters 537
B gene 1988
B19 genotype 3, 1593
B19 virus ..... 1143, 1162, 1593, 1648(L)
Bacillus cereus
buffy coat storage 949
detection methods 486, 719, 1367
BacT/ALERT culture system 1787
Bacterial artificial chromosomes 441
Bacterial contamination
ATR in PICU 1899
donor evaluation 649
of PCs 41, 220, 636, 649, 719, 949
platelet senescent cultures ..... 311(L)
rapid detection methods 1367
surveillance methods 719
Bacterial detection methods
culturing 956, 1787
in PCs 220, 476, 1787
Bacterial inactivation. *See* Pathogen inactivation methods
Bacterial infections. *See also specific bacteria*
granulocyte transfusions for 1909
BAGPM ..... 1469(E)
Bar code patient identification system 352
Basal cell adhesion molecule 668
Bedsite filtration 896
β3-Integrin 780
Bioterrorism agents ..... 678(L), 1589
Biotin labeling, of RBCs 578
Bleeding
in acute leukemia 903
gastrointestinal 919
during liver transplantation 595
self-assessment 1926
Bleeding time 731, 8S:1S
Blood banks
cord blood unit characteristics 1190
mistransfusion risk 1085
operating theater blood transaction system ..... 1848(L)
quality control 137
Blood bottles 875
Blood cell preparations/products. *See also specific blood cell preparations/products*
for coagulopathy of trauma ..... 685(E)
quality 418
Blood centers
physicians role in 854
PLT production and discard rates 991
Blood clots, in RBCs ..... 1646(L)
Blood component preparation
comparison of technical efficiency 2100
Blood conservation 1471
Blood culture systems 1787
Blood donation. *See* Donation; Predonation screening
Blood donors. *See* Donors
Blood drives 99
Blood group typing
agglutination in 448
cold agglutinins and 324
dispermic chimerism in 1978
mixed-field agglutination reaction 1463
preoperative 348
Blood irradiation quality control 34
Blood pressure, in repeated autologous blood donation 934
Blood saving protocol 1112
Blood substitutes 1104, 1892
Blood transfusion
allogeneic (*See* Allogeneic blood transfusion)
autologous (*See* Autologous blood donation)
historical asepcts ..... 165, 167(E)
mismatched, for autoimmune hemolytic anemia 1859
RBCs (*See* RBC transfusions)
risk management 2011
unmatched, decreased immunorejection 2122
for very-low-birth weight infants 1915
Blood transfusion refusal 1471
Blood viscosity 912, 1892
Blood volume changes, during cardiac surgery 392
Bloodless medicine 1471
Bloodletting ..... 165, 167(E)
BNP ..... 1453(L)
Body weight, donor reaction rates 284
Bombay phenotype 2149
Bone marrow transplantation, allogeneic
ABO-mismatched 398
IVIG usage 741
National Marrow Donor Program 1248
Book reviews 153, 868
Brazilian population 1515
Breast cancer 1199
Buffering, in RBC storage 50
Burn shock resuscitation 80

C

Calcium chloride 225
Canada
Canadian Consensus Conference 1465
donor health assessment questionnaire 2169
HCV lookback studies 690
Cancer patients 348, 668, 1199
Cardiac surgery
antithrombin during 1130
apoprotin *vs.* tranexamic acid in ..... 319(E), 327, 2208(L), 2209(R)
clinical prediction rule for allogeneic blood transfusion ..... 1072(E)
fatal TA-GVHD 885
leukoreduction in 386
need for transfusion 1120
RCV during 392
Cardiopulmonary bypass surgery
antithrombin for 1131
Hct transfusion trigger 365
RCV during 392
Carriers
HBsAg 2047
Carriers, HCMV GN-genotypes in monocytes 1754
Catheter-related complications ..... 154(L)
Caucasian population
adverse donor reactions ..... 2030(L)
adverse reactions in adolescent donors ..... 2030(L)
protein RBC antigen immunogenicity 1328
CCIs 1306
CCR7 expression 1494

CD55 1537
CD83 1494
CD133+ 1795
CD177 441
CD34+ cells
  in cord blood ..... 498(E), 507
  leukapheresis initation and 523
  quantification 403
  recovery from whole-blood filters 118
CD34+ cell counts 530, 1803
CD34+ cell mobilization
  during apheresis 1408
  with chemotherapy plus growth factors 193, 1417
  in heart failure 1424
  long-term engraftment capacity and 1934
  in multiple myeloma 180
  with rHUG-CSF 1795
  serum-free medium 126
CD3+ cells 537, 1044
CD4+ cells, CMV-specific 2053
CD8+ cells 1210, 2053
CD14+ cells 66, 537
CD16+ cells 537
CD19+ cells 537
CD45+ cells 537
CD47 expression ..... 1263(L)
CD177 expression 132
CD11b up regulation 1130
ceCF 1334
Cell-associated actively replicating virus 1580
Cell-free virus 1580
ceRA 1232
ceRT phenotype 766
CFU-GM 1934
Chagas disease 298, 1067, 1737
Chemotherapy 174, 193
Chicken anemia virus inactivation resistance 1951
Children. *See* Pediatric patients
Chimerism ..... 780, 1978. *See also* Microchimerism
Chinese blood donors 265
Chitotriosidase 1705
Chloride, in RBC storage 1543
Chronic graft-*versus*-host disease 55
CIDP 741
Cirrhosis 919, 1360
Citrate phosphate dextrose ..... 1469(E)
Cladribine-related AIHA 90
CLL 741
Clotting factors. *See* Coagulation factors
CMV
  HCMV GN-genotypes in monocytes 1754
  murine 889
  in vitro models 1580
Coagulation factors. *See also specific coagulation factors*
  mild abnormalities 1279
  in PCT-treated plasma 1168
  proteomic analysis 377
Coagulopathy
  rFVIIa therapy 919
  of trauma patients ..... 685(E)
Cobe Spectra continuous-flow cell separator 398, 966
Cold agglutinins 324, 1521
Collection volume, donor reaction rates 284
Compatibility testing, for same-day surgery ..... 321(E)
CompoDock S2 sterile connection device 418
Compound adsorption device 562
COM.TEC cell separator 66
Confidentiality, refusal of blood transfusion 1471
Contingency planning, refusal of blood transfusion 1471
Continuous ambulatory blood pressure monitoring, in repeated PABD 934
Coombs, Robert Royston Amos (Robin) 1854
Cord blood
  CD177 expression 132
  characteristics 1190
  engraftment potential 1803
  National Marrow Donor Program ..... 1080(E)
  transplant outcomes 2063
  in vitro assays of hematopoietic cells ..... 498(E), 507
Cord blood transfusion
  adult recipient outcomes 2063
  autologous 1049
  telomere length changes 1038
Coronary artery bypass grafting
  aprotinin *vs.* tranexamic acid in 327
  leukoreduction in 386
  RBC storage time and 1712
Cost effectiveness analyses 523, 956, 1624
Counseling, physicians role in 854
Crawford antigen 1334
Creutzfeldt-Jakob disease
  donor deferral policies 461, 2011
  leukodepletion and 407
  prion removal/inactivation from blood components 652
Critically ill patients 1286
Cromer antigens 1537
Cross-reactivity ..... 1847(L)
Cryopoor-plasma, for TTP 74, 688
Cryopreservation 230, 8S:1S
Cyclophosphamide 174, 1934
Cytokines
  PLT storage and 800, 828, 1184
  PLT-DC interactions 818
  RhIG prophylaxis 1316
Cytomegalovirus-specific CD4 2053
Cytotoxic T cells, tetanus toxoid and 1210

D

D antigen 766, 1343, 2122, 2156
Dalteparin 624
DARE 606
DAT 1237
DEHP exposure ..... 503(E), 1457(L)
DEL ..... 1061(L)
Deletions, in-frame triplet in *RHD* 2156
Demerol PCA, with RBC transfusion 372
Demographics
  paternity tests and 849
  risk-behavior reporting 289
Dendritic cells
  activation during ECP 55
  cell yield 1494
  extracorporeal phototherapy and ..... 6(E)
  PLT interactions 818
Dental surgery 919
Deviation bags 476
Diego blood system 454
Digoxigenin, for RBC labeling 578
Dilaudid PCA, with RBC transfusion 372
Dilution, in RBC storage 50
Direct transfusions 497
Disinfection, of autologous RBCs 8S:1S
Dispermic chimerism 1978
Disposable-bag systems 2100
Disseminated histoplasmosis 1221
DNA polymorphisms 554
DNA sequence analysis
  ABO genotyping ..... 780, 1259(L)
  HBV quantificaton 1829
  Kuwaiti population 773
  LOCR antigen 1689
  RH43 1334
  RHD alleles 1343
DNA-based assays. *See* Nucleic acid testing

Documentation, of transfusion refusal 1471
Dombrock blood group system 244
Donation
  autologous preoperative (*See* Autologous blood donation)
  barriers to 545
  decision-making 980, 996
  eating before 877
  during HBV window-period 1138
  psychological aspects 1006
  time 99
  whole-blood, menstruating females and 1667
Donor history questionnaire, abbreviated 1745
Donor lymphocyte collections 1044
Donor recruitment
  advertising 996
  African Americans 1388
  donation decision and 980
  MSM deferral criteria ..... 869(L)
  randomized controlled trials 1090
  strategies ..... 501(E)
  TTI risk in Chinese donors 265
Donor registry 2115
Donor return rates
  adverse events and 1374
  decision to donate and 980
  phlebotomist interpersonal skill 1394
  predonation anxiety 1006
Donors. *See also* Predonation screening
  adverse reactions ..... 1374, 1394, 2030(L)
  blood volume regulation 1609
  Canadian donor health assessment questionnaire 2169
  Chinese, TTI risks 265
  counseling 695
  deferrals 461, 1997
  deterrents for 545
  evaluation in bacterial contamination 649
  first-time 284
  G-CSF stimulated 186
  Hb testing 2176
  HBV-positive 1256
  with HCV liver disease 278
  HCV-positive 469, 1719
  HIV-infected, differential transmission from ..... 156(L)
  IgA-deficient 10
  medication history 1402
  menstruating females 1667
  Mexican, West Nile virus detection in 111
  molecular profiling 841
  National Marrow Donor Program ..... 1080(E), 1248
  non-cytokine-stimulated, CD14+ cell collection in 66
  reaction rates 284
  research on ..... 1069(E)
  risk-behavior assessment 289
  Staphylococcus aureus nasal carriage ..... 310(L)
  travel-related deferrals 1641
2,3-DPG 137, 1292, 1469
DRB1* restriction molecules 1328
Dry-heat inactivation ..... 1648(L)
Duffy blood group system 250, 630, 1328, 1682
DVA(KOU) allele 606

E

Ectonucleotidases 1018
Education
  fo donor recruitment 1388
  physicians role in 854
EIA
  ADAMTS13 1444
  Chagas disease 298
  HCV 695
  HTLV lookback 703
Elastase 1130
Elderly TA-GVHD ..... 878(E)
ELISA
  anti-HCV 708
  Chagas disease 298
  IgA-deficient blood donor registry 2115
  neopterin 1886
  Trypanosoma cruzi 1737
  WNV 111
E-mail recruitment 1090
Endothelial progenitor cells 1795
Engraftment potential, cord blood 1803
Enhanced Bacterial Detection System 220
Epidemiologic investigations, of infected blood donors ..... 1663(E)
Epstein-Barr virus 2035
Erythrophagocytosis 2035
Erythropoiesis 339
Erythropoietin 339, 1112, 1616
Erythrovirus B19 ..... 1162, 1593
Escherichia coli
  detection methods 1367
  inactivation 949
Ethiopian population 606
Ethnicity 469, 980, 2149
Etoposide 174
Europe
  HBV positive donors 1256
  PLT production and discard rates 991
Exchange transfusion 339
Exercise testing 1484
Exocytic vesiculation (vesicles) 143
Extracorporeal blood volume 1609
Extracorporeal photophoresis ..... 6(E), 55

F

Febrile nonhemolytic reactions 1899
Federal government National Marrow Donor Program ..... 1080(E)
Fetomaternal alloimmunization 2138
Fetomaternal hemorrhage ..... 1271(E)
FFP
  ADAMTS-13 ..... 1261(L)
  amotosalen-treated 1693
  in Finland 1921
  PT and 1279
  TRALI incidence and 1478
  for TTP ..... 74, 688, 1659(E), 1693
  vs. CPP 74
  VWF loss ..... 1057(L)
Fibrin 1130
Fibrinogen 8S:1S
Fibroblasts 225
Filgrastim 1934
Filtration
  in-line, of autologous whole blood 811
  WBC (*See* Leukoreduction)
Finland transfusion practices 1921
Flow cytometry
  CD34+ cell count viability 530
  cord blood NRBCs 403
  KEL1 antigen 1879
  PC sterility testing 41, 486
  RBC double-labeling method 578
  residual RBCs in blood products 966
Fluorescence-activated cell sorting 1367
Fluorinated ethylene-propylene 1491
FOCUS Trial 2192
Freeze-drying storage, of platelets 1029
Fungal infections 1909
FUT1 loci allele 2149
FUT2 loci allele 2149
FVIIa 919
FVIII ..... 1292, 1648(L)

G

G829A mutation ... 780
Gambro Trima Accel ... 1601
Gamma irradiation ... 34, 800
Gastrointestinal bleeding ... 919
Gastrointestinal reflux disease ... 1537
Gaucher disease ... 1705
G-CSF granuloctye stimulation
  mobilized granulocyte transfusions ... 1849(L)
G-CSF granulocyte stimulation ... 1(E)
  CD34+ yield, dose and ... 180
  in heart failure ... 1424
  for hemoprotenitor cell transplantation ... 14, 186
  for pediatric patients ... 1909
  respiratory disturbances ... 186
GeneScan fragment analysis ... 1259(L)
Genotyping
  ABO ... 348, 1259(L), 1978
  HNA-5a ... 1515
  Kell ... 1879
  SSP ... 1510
Gen-Probe ... 111
German population ... 766
Glucose, in stored PLTs ... 942, 973
Glutathione S-transferase T1 ... 1505
Glycoproteins
  IBα ... 2090
  Kell ... 1879
  Lutheran ... 668
Glycosorb ABO column ... 1568
Glycosphingolipids, in NOR RBCs ... 1264(L)
Granulocyte collection ... 1849(L)
Granulocyte transfusions
  after allogeneic transplant ... 14
  dose ... 1(E)
  G-CSF stimulation (*See* G-CSF stimulation)
  pediatric ... 1909
GSTT1 antigen ... 1505
Guillian-Barre syndrome ... 741

H

Haemonetics MCS Plus ... 1601
HA-1^{H} cytotoxic T cells ... 1210
HAV ... 1143
Hb
  decrease ... 1484
  in HIV+ patients with positive DAT ... 1237
  in RBC units ... 137
  regeneration after donation ... 1667
  in sickle cell anemia ... 105
  in whole-blood donors ... 2176
Hb-based oxygen carriers ... 1104, 1859
HBsAg ... 1138, 2047
HBV
  donor deferral ... 1997
  in Dutch donors ... 1729
  early phase infection ... 1886
  NAT ... 1256, 2028(L), 2047
  posttransfusion hepatitis ... 1624
  quantificaton and infectivity ... 1829
  serologic assays, cross-reactivity ... 1847(L)
  window-period blood donation ... 1138
Hb-vesicles ... 339
HCMV GN-genotypes ... 1754
Hct-to-viscosity ratio of RBCs ... 912
HCV
  antigen testing in pools ... 1822
  assays ... 708
  childhood-acquired ... 1360
  demographic correlates of viremia ... 469
  donor deferral ... 1997
  in Dutch donors ... 1719, 1729
  early phase infection, neopterin levels in ... 1886
  health-related quality of life ... 278
  lookback studies ... 690
  predonation screening ... 1380, 2033(C)
  serologic assays, cross-reactivity ... 1847(L)
Health-reiated quality of life ... 278
Heart failure ... 1424
Heat treatment, SARS-CoV inactivation ... 1770
Hematocrit ... 365, 1892
Hematomas ... 2184
Hematopoietic cells
  recovery, ABO-mismatched BMT ... 398
  stem cell transplants ... 14, 169, 186, 1038, 1934
  in vitro cord blood assays ... 498(E), 507
Hemoglobin-vesicles ... 339
Hemolysis
  after ATG ... 1245
  ATR in PICU ... 1899
  in sickle cell anemia ... 105
Hemolytic anemia, IgM-mediated ... 2035
Hemolytic disease of fetus and newborn
  anti-Di^{b} ... 454
  RhIG prophylaxis ... 1271(E), 1316, 1652(E)
Hemolytic transfusion reactions ... 244
Hemorrhage, fetomaternal ... 1271(E)
Hemostasis, by rehydrated lyphilized PLTs ... 1943
Hemotherapy ... 165, 167(E)
Heparin ... 683
Hepatectomy, partial ... 919
Hip surgery ... 1097
Histoplasmosis ... 1221
History of transfusion medicine
  blood bottles ... 875
  blood grouping ... 448
  blood transfusions ... 165, 167(E)
  direct transfusions ... 497
  medical photography ... 1855
HIV
  differential transmission ... 156(L)
  early phase infection ... 1886
  Hb levels with positive DAT ... 1237
  IVIG usage ... 741
  predonation screening ... 1380, 2033(C)
  serologic assays, cross-reactivity ... 1847(L)
  transfusion risks ... 1624
HLA antibody prevalence ... 754
HLA class II restriction analysis ... 1328
HLA haplotype ... 885
HLA typing ... 1978
HLA-DR ... 1863, 1870
HLA-matched PLTs, shipping ... 1306
HNA-4a antigen ... 151
HNA-5a antigen ... 151, 1515
Hold time, before PRP processing ... 942, 1292
Hospital transfusion services ... 352, 862
HPA-1a ... 790
HTLV
  in Dutch donors ... 1729
  lookback program ... 703
  serologic assays, cross-reactivity ... 1847(L)
  serologic tests ... 1647(L)
Human serum albumin. *See* Albumin, human serum
Hydroxyethyl starch ... 1705, 1892
Hyperbilirubinemia ... 454
Hyperhemolysis ... 105
Hypertension ... 1104
Hypertriglyceridemia ... 1853
Hypervariable regions ... 554
Hypogammaglobulinemia ... 741
Hypotension ... 8S:1S
Hypothermia ... 8S:1S
Hypotonic shock response ... 236
Hypovolemia ... 365, 8S:1S, 1609

I

i phenotype 1982
ICU
  acute pediatric transfusion reactions 1899
  PLT transfusions 1286
  RBC storage time in CABG 1712
  TRALI incidence 1465, 1478
Idiopathic thrombocytopenic purpura 741
IgA deficiency 10
IgA-deficient blood donor registry 2115
IGHV3 superspecies genes 2162
IgM antibodies ..... 1260(L), 2035
IGnT allele, novel 1982
IL-6 1184
IL-8 1184
IL-10 ..... 55, 1494
IL-12 1494
Immunogenicity of RBCs 1328, 1526
Immunosorption, of ABO antibodies 1568
Immunurejection 2122
Inab phenotype 1537
Inconvenience, as donation barrier 545
InDel assays 1870
Infants
  autologous cord blood transfusion 1049
  estimating blood needs for 1915
  IVIG usage 741
Inflammation 1526
Inherited bleeding disorders 1360
Innovations, in transfusion medicine 854
Inositol hexaphosphate-adenosine triphosphate-polyethylene glycol 8S:1S
Inositol hexaphosphate-polyethylene glycol 8S:1S
Integrins 780, 1943
INTERCEPT Blood System 1168
Interlaboratory comparisons ..... 498(E), 507
International transfusion practice 903
Intersol 800
Iron
  absorption 1616
  depletion 1667
  IV 1112
  oral supplementation 1667
IR-WP model 1624
Isoelectric focusing ..... 872(L), 1959
ITT principle ..... 881(E)
IVIG 741

J

Jehovah's Witnesses 1471
JK blood group 630
Js^a antigen 1510
Js^b antigen 1510

K

KALT 1323
Kawasaki disease 741
Kell blood group system
  antigens 1323, 1328, 1879
  genotyping 1510
  RBC alloantibodies 250, 630
Kidney disease ..... 327, 1104, 2207(L)
Kidney transplantation 1505, 1568
Klebsiella pneumoniae
  buffy coat storage 949
  detection methods *486*, 1367
Korean donors 2128
KTIM 1323
Kuwaiti population, ABO blood group in 773

L

Lactate, in stored PLTs 942, 973
Latent virus 1580
LDH, in stored PLTs 973
Leishmania
  removal by leukodepletion filters 315, 896
  risk to blood supply 1641
Lenograstim. *See* GCF
Leukapheresis 523, 1044
Leukemia 903, 1926
Leukoreduction (leukodepletion)
  adhesion of RBC products 1561
  of autologous whole blood 811
  in cardiac surgery 386
  microvesicles and 407
  postoperative infection and ..... 492(L)
  transfusion-associated microchimerism and 1863
Leukoreduction filters
  CD34+ cell recovery 118
  Leishmania removal 315, 896
  LEUKOSEP HRC-600-C system 1311
  mononuclear cell recovery 2083
  PBMNC recovery from 537
  Trypanosoma cruzi removal 1067
$Leu_{33}Val$ mutation 780
Lifetime transfusion rates 1491
Listeria monocytogenes 305
Liver biopsy 919
Liver transplantation
  antifibrinolytics in 595
  anti-GSTT1 in 1505
  rFVIIa therapy 919
LOCR antigen 1689
Lookback studies 690, 703
Low-molecular-weight heparin 624
Lutheran blood group system 668, 1011
Lymphoma 174, 1417
Lysosomal storage disease, acquired 1705

M

Maco Biotech HP01 medium 126
Macrophages
  glycoproteoin IBα in platelet phagocytosis 2090
  PLT binding and phagocytosis 1432
  WNV replication in 659
MAIPA assay 1226
Malaria 461
Manufacturer quality control 137
Massachussetts General Hospital IVIG usage 741
Maternal antigens, noninherited 1856
Maternal typing ..... 199, 1454(L)
Matrix metalloproteinases 1199
Medical photography 1855
MEHP ..... 503(E)
Membrane fusion, exocytic vesiculation and 143
Methemoglobinemia ..... 1060(L)
Methoxypolyethylene glycol 2122
Mexico
  transfusion-associated Chagas disease in 298
  WNV detection in blood supply 111
MGDF 1934
Microchimerism
  assays 1870
  posttransfusion 1856, 1863
Microvesicles
  leukodepletion and 407
  RBC storage 143
Minisatellite 1988
Mirasol PRT treatment 642, 1553
Misidentification prevention 352
Mismatched blood transfusion 1859
Missense mutation 1982
Mistransfusion risk 1085
Mixed-field agglutination 1463
Mixed-field agglutination reaction 1463
MMN 741

MNS blood group 630
Model systems, CMV 1580
Modified fluid gelatin 1892
Molecular investigations, of infected blood donors ..... 1663(E)
Monoclonal antibodies (MoAbs) 1011, 1444
Mononuclear cell counts ..... 498(E), 507
Mononuclear cells
  collection methods 118, 1044, 2083
  HCMV GN-genotypes 1754
  Leishmania amastigotes in 896
  Mirasol PRT-treated 642, 1553
  residual RBCs and 966
  WNV replication in 659
Morphine PCA, coadministered with RBC transfusion 372
Mortality
  ATR in PICU 1899
  lifetime transfusion rates and 1491
  plasma exchange complications in TTP-HUS ..... 154(L)
  TA-GVHD 885
mRNA expression, CD177-specific 132
MSM deferral criteria ..... 869(L)
MSs blood group system 250
mtDNA polymorphisms 554
Multicomponent apheresis 2184
Multiple myeloma 174, 180, 1417, 1934
Multiple organ dysfunction score 80
Multiple sclerosis 741
Multiple transfusions, HLA antibody prevalence 754
Mutations
  ABO gene 434
  G829A 780
  KEL 1323
  $Leu_{35}Val$ 780
  missense 1982
  platelet β3-integrin gene 2138
Myasthenia gravis 741
Myelodysplastic syndrome 1463

N

NANBH 1624
Nanofiltration, antibody-enhanced 1143
Nasal carriage ..... 310(L)
NAT. *See* Nucleic acid testing
National Marrow Donor Program ..... 1080(E), 1248
NB1 441
Necrotizing faciitis 741
Need for transfusion, in cardiac surgery 1120
Neonatal transfusion 757
Neopterin 1886
Netherlands
  bacterial culture and pathogen reduction 956
  HCV in donors 1719
  platelet transfusion safety 476
  transfusion-transmitted infections in 1729
Neuropathy 741
Neutropenia, granulocyte transfusion therapy ..... 1(E), 1901
Neutrophil recovery, after chemotherapy 1417
Noncellular blood products, SARS-CoV inactivation 1770
NOR RBCs ..... 1264(L)
Nucleated RBCs
  in cord blood ..... 498(E), 507, 1803
  flow cytometric evaluation 403
Nucleic acid testing
  for bioterror agents ..... 678(L)
  donors 841
  HBV 1256, 1886, 2047, 1256
  HCV 469, 695, 1822, 1866
  individual ..... 1138, 2028(L)
  minipool 2047
  predonation screening 1624
  rapid bacterial detection 1367
  with serologic tests ..... 1663(E)
  WNV (*See* West Nile Virus NAT)

O

Obituary, Robert Royston Amos (Robin) Coombs 1854
Octanoic acid treatment 1770
Operating theater blood transaction system ..... 1848(L)
Orthopedic surgery 1097, 1484
Osteocalcin 225
Oxygen affinity 8S:1S
Oxygen carriers, artificial 1104, 1892
Oxygen delivery, RBC storage 2014

P

p24 antigen 1624
Pall Bacterial Detection System 220
Pancreatitis 1853
Para-Bombay phenotype 2149
Parosysmal nocturnal hemoglobinuria 1244
Parvovirus B19 ..... 1143, 1162, 1593, 1648(L)
Paternity tests
  demographics and 849
  one- *vs.* two-parent 199
Pathogen inactivation methods
  coagulation factors and 1168
  cost effectiveness 956
  dry-heat ..... 1648(L)
  gamma irradiation 34, 800
  resistance 1951
  S-303 1778
  SARS-CoV 1770
  thiazole orange 213
  with thiazole orange 213
Patient identificaton bar code system 352
Patient self-assessment, of bleeding symptoms 1926
Patient-controlled analgesia 372
PBPC mobilization
  with chemotherapy and pegfilgrastim 1417
  in heart failure 1424
  in multiple myeloma 180
PBPCs
  recovery from leukodepletion filters 537
  recruitment during apheresis 1408
  yield 174
PBSC-LYM program 55
PCR
  CMV model of infection 1580
  Dombrock blood group assay 244
  HBV quantificaton 1829
  novel IGnT allele 1982
  RT-PCR 889, 1870
  SSP-PCR 780
  SSS-PCR 1510
PCR-RFLP 1515, 1988
PCT-treated plasma 1168
PCT-treated PLTs 731
PDGF 225
PDGF-AA
  release during platelet storage 1184
Peanut ingestion 1853
Pediatric patients
  acute transfusion reactions 1899
  acute transfusion reactions in ICU 1899
  childhood-acquired HCV 1360
  cord blood transplant recipient outcomes 2063
  granulocyte transfusions 1909
  HIV/AIDS IVIG usage 741
  very-low-birth weight infants 1915
Pegfilgrastim mobilization 180, 1417
Perfluorocarbon emulsion 1892
Peripheral blood progenitor cell transplantation 14, 169, 186
pH
  intracellular 1029
  PLT storage ..... 871(L), 1300, 942
  post-platelet wash 236
  RBC storage 137, 1543

Phage display technology 1011
Phagocytosis 1432, 2090
Pharmacist error 683
Phenotypes
  ceRT 766
  D antigen 2156
  $A_{el}B_{el}$ 780
  i 1982
  Para-Bombay 2149
  Rh 1232
  weak ABO 434
Phlebotomist interpersonal skill 1394
Phosphate ion-exchange resin 8S:1S
Photochemical treatment
  with amotosalen and UVA 731, 1168, 1693
  Mirasol 642
  PLTs 24, 424, 562, 800
Photopheresis 683
Photosensitive dyes 213
Phthalates ..... 503(E)
Physicians role 854, 862
Pica 1853
Plasma
  black 1267
  "muddy" appearance ..... 1060(L)
  platelet ADP response in 204
  solvent/detergent treatment 2100
  TRALI incidence and 1478
  viscosity 1892
  volume 392
Plasma derivative manufacture 1143
Plasma exchange
  arsine toxicity 1576
  complications in TTP-HUS ..... 154(L)
  hypertriglyceridemia 1853
Plasma proteins, baboon 8S:1S
Plasma transfusion therapy ..... 1268(E)
Plasmapheresis
  DEHP exposure ..... 1457(L)
  with HES 1705
  intermittent-flow 1609
  LMWH in 624
Plasma-related complications ..... 154(L)
Platelet activation 8S:1S
Platelet activation inhibition 1130
Platelet additive solutions
  ADP response 204
  cytokine levels 800
  hold time 942, 1292
  PRP-PCs and 835
  storage temperature 828
  storage time 236, 973
Platelet aggregation 204, 236, 1018
Platelet antibodies 1226
Platelet antigens 841
Platelet β3-integrin gene mutation 2138
Platelet binding 1432
Platelet concentrate
  bacterial contamination 636
  bacterial detection methods 220, 636
  buffy coat-derived 828, 949, 991
  extended storage 1763
  flow cytometry-based sterility testing 41
  lipemic 877
  pH ..... 871(L), 1300
  photochemical treatment process 562
  in plasma *vs.* additive solution 204
  platelet-rich plasma method 572
  from PRP 1292
  residual RBCs 966
  resting time 572
  shipping effects 1306
  Staphylococcus aureus–contaminated ..... 310(L)
  sterile connection devices and 418
  sterility testing 486
  survival 8S:1S
  viability assessment 257
  whole-blood derived 572
Platelet count
  bleeding and 903
  neonatal transfusion 757
  response to PLT transfusion 1286
  storage of WBC-reduced RBCs and 589
Platelet cryopreservation methods 230
Platelet gel formation 225
Platelet releasate 225
Platelet shape 1018
Platelet split products 757
Platelet storage
  ADP response in synthetic media 204
  after photochemical treatment 424
  buffy coat-derived PCs 949
  cytokines and 1184
  filter-LR PRP preparations 257
  freeze-dried 1029
  hold time before adding PAS 942, 1292
  of PCT PLTs 800
  pH 1300
  plasma ectonucleotidases 1018
  postwash 236
  senescent cultures ..... 311(L)
  temperature 828
  time 757, 973, 1763
Platelet transfusions
  adverse reactions 1813
  bleeding outcome in leukemia 903
  with 7-day old PCT PLTs 424
  dose consistency 24
  in ICU 1286
  neonatal 757
  and RBC transfusion for anemic thrombocytopenic purpura ..... 2210(L), 2211(R)
  safety practices in Netherlands 476
  self-assessment of bleeding 1926
  Streptococcus agalactiae sepsis after 649
  transfusion-transmitted *Serratia marcescens* ..... 679(L)
Platelet-derived mediator 1813
Platelet-derived microvesicles 407, 1199
Plateletpheresis
  blood center rates 991
  DEHP exposure ..... 1457(L)
  high-dose 1601
  instruments/equipment 1601
  multiple, single-needle procedures 1601, 2004
  recovery/survival characteristics 257
  skin disinfection and deviation bag for 476
Platelet-rich plasma 225
Platelets
  allogeneic, detection of 554
  baboon 8S:1S
  bacteria detection methods 636
  discard rate 991
  interctions with DCs 818
  Listeria monocytogenes in 305
  Lyphophilized reconstituted 8S:1S
  phagocytosis of 2090
  photochemically treated 24, 424, 562, 800
  production rate 991
  purinergic receptors 1018
  rehydrated lyphilized 1029, 1943
  in vivo recovery 257
  washing 236
  WB-derived 257, 1787
Polycythemia vera 441
Polyethylene glycols 8S:1S 2122
Polymorphisms 1870

Polystyrene 1491
Polyvinylchloride ..... 503(E)
Porcine circovirus 1951
Postoperative length of stay 386
Postoperative patients, underestimation of anemia severity in ..... 317(E)
Posttransfusion hepatitis 1624
PPP 225
Predonation screening
  abbreviated donor history questionnaire 1745
  for bioterror agents ..... 678(L)
  Canadian donor health assessment questionnaire 2169
  donor history accuracy 1402
  face-to-face interviewing ..... 1380, 2033(C)
  HCV infection ..... 1381, 2033(C)
  health history questions 1997
  HIV infection ..... 1380, 2033(C)
  infected donors ..... 1663(E)
  transfusion risk and 1624
  travel questions, deferral policies and 461
  WNV ..... 272, 2036, 2036(E)
Pregnancy ..... 1456(L), 1667, 1853
Premature infants 1049
Preoperative blood sample, expiration date extension 348
Prescription medications, donor history accuracy 1402
Prewarming, for Rh antibody testing 1521
Prion protein affinity ligands 1152
Prions 407, 652
PRISIM Chagas assay 1737
Prolastin 1959
Propidium iodide-positive events 589
Propionibacterium acnes 949
Prostaglandin E_2 1316
α_1-Proteinase inhibitor products ..... 872(L), 1959
Proteomic analysis 377
Prothrombin complex concentrates 377
PRP-PCs 257, 835
PRV-1 441
P-selectin expression 236
Pseudomonas aeruginosa 719, 949
PT-INR ..... 919, 1268(E), 1279
Pulmonary edema 1478
Pulsed-field gell electrophoresis 305
Purinergic receptors 1018

Q

Quality
  of autologous whole blood 811
  of platelets after 7-day storage 973
  poststorage RBCs 137
  WB storage before PRP processing 1292
Quality control, cord blood 403
Quantification
  CD34+ cells 403
  HBV 1829

R

Rabbit RBC stroma ..... 1260(L)
Race
  donation decision and 980
  HCV RNA negativity 469
Radiofrequency identification 1085
Radiosensitivity, of T cells 34
Randomized controlled trials
  amotosalen-treated FFP in TTP 1693
  ANH in hip surgery 1097
  donor recruitment strategies 1090
  FOCUS 2192
  REDS-II ..... 1663(E)
  SPRINT trial 24, 562
  TTP ..... 1659(E)
RANTES 1184
Rapid bacterial detection tests 1367
RBC adherence, storage duration and 1561
RBC alloantibodies 250, 630, 754, 1682
RBC alloantigens 250, 1526
RBC antigens
  donor molecular profiling 841
  low-frequency 1510
RBC autoantibodies 1859
RBC depletion, in bone marrow processing 398
RBC exchange, for arsine toxicity 1576
RBC membrane flexibility 137
RBC microvesicles 407
RBC senescence 578
RBC storage
  adhesion to endothelium and 1561
  baboon 8S:1S
  buffering and dilution in 50
  CD47 expression ..... 1263(L)
  cold, effect on VWF ..... 1057(L)
  consequences in critical illness 2014
  with improved 2,3-DPG 1543
  microvesiculation 143
  quality criteria 137
  RBC functionality and ..... 1469(E)
  thiazole orange pathogen reduction 213
  time 589, 1292, 1712
RBC survival
  baboon 8S:1S
  in sickle cell anemia 105
RBC transfusions
  antifibrinolytics in liver transplantation and 595
  coadministered with PCA 372
  critical illness, storage effects 2014
  and PLT transfusion for anemic thrombocytopenic purpura ..... 2210(L), 2211(R)
  trigger, Hct value as 365
  for very-low-birth-weight infants 1915
RBCs
  baboon 8S:1S
  blood clots in ..... 1646(L)
  deglycerolized 1178
  leukoreduced 418, 589, 1311
  postdeglycerolization 1178
  quality criteria 137
  residual in blood products 966
  S-303 pathogen inactivation treatment 1778
  T cell inactivation in 34
  vesiculation 143
  viability 137
  washing 137
  WBC-reduced 589
RBV, during cardiac surgery 392
REDS-II ..... 1663(E)
Renal disease ..... 327, 1104, 2207(L)
Research
  donor ..... 1069(E)
  on infected blood donors ..... 1663(E)
  National Marrow Donor Program ..... 1080(E)
  physicians role in blood center 854
Resource utilization 523
Respiratory failure 1478
Reticulocyte count 105
Reticulocytes, baboon 8S:1S
Retrovirus Epidemiology Donor Study-II (REDS-II) ..... 1663(E)
Retroviruses ..... 1276(E)
RFLP 1988
rFVIIa 919
RH43 1334
Rh55 1689
Rh blood group system
  alloimmunization 250
  antibody testing 1521
  low-incidence antigens 1689
  phenotypes 1232
  preoperative typing/screening 348

RBC alloantibodies in nonhematologic alloimmunized cohort ... 630
weak D cells ... 1061(L)
RH haplotypes ... 1343
RH5 variant ... 1232
RHCE allele ... 1334
RHCE gene ... 766
RHD alleles ... 606, 1343, 2156
RhD typing
on cell-free fetal DNA from maternal plasma ... 2142
for D- East Asian persons ... 2128
false positive ... 1454(L)
in southeast Asian populations ... 95
RHD(T201R,F223V) cluster analysis ... 606
Rheology ... 912, 1892
RhIG prophylaxis ... 1271(E), 1316, 1652(E)
rHu-EPO ... 1616
rHuG-CSF ... 1795
RIBA ... 695
RIPA ... 1737
Risk profiles, of infected donors ... 1729
Risk-behavior reporting ... 289
RT-PCR ... 889, 1870

S

S-303 pathogen inactivation treatment ... 1778
Safety ... 2011
abbreviated donor history questionnaire ... 1745
acute normovolemic hemodilution ... 1075(E)
mistransfusion risk ... 1085
retroviral ... 1276(E)
rFVIIa therapy ... 919
smallpox vaccination ... 1589
Same-day surgery ... 321(E)
SARS-CoV inactivation methods ... 1770
sCD40L ... 1813
Scrapie brain ... 652
Septic shock ... 679(L)
Sequencing ... 554
Serologic tests
with HCV NAT ... 695
HTLVs ... 1647(L)
with NAT ... 1663(E)
for smallpox vaccinees ... 1847(L)
Trypanosoma cruzi ... 1737
Serratia marcescens
detection in PLT concentrate ... 719
inactivation during storage ... 949
transfusion-transmitted ... 679(L)
Sex, donor reaction rates ... 284
Shipping, of PLTs ... 1306
Sickle cell disease
acute chest syndrome ... 1657
B-CAM/Lu expression ... 668
educational donor recruitment video ... 1388
Hct-to-viscosity ratio of RBCs ... 912
hyperhemolysis ... 105
Simian foamy virus infection ... 1352
Skin disinfection method ... 476
Smallpox vaccination ... 1589, 1847(L)
SNP ... 841
Solid organ transplantation
false-positive fetal *RHD* typing ... 1454(L)
IVIG usage ... 741
liver ... 595, 919, 1505
Solid-phase scanning cytometer ... 1367
Solvent-detergent plasma ... 1261(L), 1770, 2100
Southeast Asian populations ... 95
Spanish population ... 616, 1138
Splenomegaly ... 339
Spongiform encephalopathy agents
removal/inactivation from blood components ... 652, 1152
SPRINT trial ... 24, 562
SSCP ... 773
SSP genotyping ... 1510
SSS-PCR ... 780, 1510
Staphylococcus aureus
buffy coat storage ... 949
detection in PLTs ... 486, 719
PLT contamination ... 310(L)
rapid detection methods ... 1367
Staphylococcus epidermidis ... 486, 949
Sterile connection devices ... 418
Sterility testing
comparisons ... 2071
of platelet concentrates ... 486
Streptococcus agalactiae sepsis ... 649
STR-PCR typing ... 780
Student donor reaction rates ... 284
Surveillance programs ... 719, 1729
Swiss population ... 766

T

TACO ... 1453(L), 1478
TA-GVHD
elderly ... 878(E)
extracorporeal phototherapy ... 6(E)
fatal ... 885
prevention ... 34, 642, 1553
Taiwan patients ... 95, 1982
T-cells. *See also specific types of T-cells*
HCMV-specific ... 516
radiosensitivity of ... 34
Telephone automated system, for risk-behavior reporting ... 289
Telomere length changes ... 1038
TEPITOPE program ... 1328
Terumo sterile connection device ... 418
Tetanus toxoid ... 1210
Therapeutic plasma exchange. *See* Plasma exchange
Thrombin ... 225, 1943
Thrombocytopenia
alloimmune ... 790
bleeding time correction ... 731
7-day old PCT PLTs for ... 424
platelet transfusion dose consistency ... 24
Thrombocytopenic purpura
anemic ... 2210(L), 2211(R)
idiopathic ... 741
Thrombotic microangiopathy ... 1221
Tissue culture methods ... 1494
TNC count ... 498(E)
Torquetenovirus ... 1593, 1951
Total hip replacement surgery ... 1484
Total knee replacement surgery ... 1112
Training, physicians role in ... 854
TRALI
BNP measurement ... 1453(L)
endothelial activation ... 1455(L)
epidemiology in ICU ... 1478
incidence ... 1465
Tranexamic acid
in cardiac surgery ... 319(E), 327, 2208(L), 2209(R)
in liver transplantation ... 595
Transcription-mediated amplification test ... 111, 1138
Transforming growth factor-β ... 225, 1184, 1316
Transfusion lookback studies ... 690, 703
Transfusion medicine history. *See* History, of transfusion medicine
Transfusion reactions, acute ... 1899
Transfusion requirement prediction ... 1120
Transfusion Risk Understanding Scoring Tool ... 1120
Transfusion triggers ... 365, 1112, 1286
Transfusions. *See also specific types of transfusions*
Transfusion-transmitted infections. *See also specific infections*
Chagas disease in Mexico ... 298
CMV ... 889
erythrovirus B19 ... 1593

individual NAT and ..... 2028(L)
Leishmania 1641
leukodepletion and 407
in Netherlands 1729
prion removal/inactivation from blood components 652
risks in Chinese donors 265
Serratia marcescens ..... 679(L)
SFV 1352
viral 1624
West Nile virus ..... 2036(E)
Translation-initiator mutation 434
Transmissible spongiform encephalopathy 652, 1152
Trauma patients
coagulopathy of ..... 685(E)
posttransfusion microchimerism 1856
rFVIIa therapy 919
transfusion-associated microchimerism and 1863
Travel questions, donor deferrals and 461
Triglycerides 1853
Trima cell separators 966, 2004
Trypanosoma cruzi 298, 1067, 1737
Trypanosomiasis, American 298
T-sol 800
TTP
ADAMTS 13 activity 1444
amotosalen-treated FFP for 1693
management 687
in pregnancy ..... 1456(L)
randomized clinical trials ..... 1659(E)
vWF pathogenicity in 74
TTP-HUS ..... 154(L)

U

Ultralarge von Willebrand factor 74
Umbilical cord blood. *See* Cord blood
Upshaw-Schulman syndrome 1444
UV irradiation
with amotosalen 731, 1168, 1693
SARS-CoV inactivation 1770

V

Vaccinia viremia 1589
Variola virus NAT ..... 678(L)
Vasculogenesis, therapeutic 1795
VEGFR-2 1795
Venesection 165
Viability
of apheresis *vs.* PRP platelets 257
dendritic cells 1494
of stored RBCs 8S:1S
..... 1778
Viral infections. *See also specific viruses and viral infections*
in deferred donors 1997
erythrovirus B19 1593
pathogen inactivation (*See* Pathogen inactivation methods)
retroviruses ..... 1276(E)
transfusion-transmitted 1624
Viscosity, whole blood 1892
Volume expanders 1892
von Willebrand factor
cold storage effects ..... 1057(L)
plasma levels, ABO blood group and 1836
in rehydrated lyphilized PLTs 1943
storage effects 1292
in TTP 74
VP16 174

W

Waldenström's macroglobulinemia 90
Warm autoimmune hemolytic anemia 90
Washing
PLT 236
RBC 137
WBC activation 1130
WBC counts 589
WBC inactivation, by Mirasol 642
WBC reduction. *See* Leukoreduction
WNV
detection methods ..... 111, 272, 2036(E)
replication in monocytes-macrophages 659
self-reported symptoms 272
transfusion-associated transmission ..... 2036(E)
Wound healing, platelet gel for 225

Y

Yersinia entercolitica 949

Z

Zemaira 1959